Zoe Hughes

VP, Head of Biology

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (10)

Gerard Marek

Chief Medical Officer

Boehringer Ingelheim Pharmaceuticals Inc

UNITED STATES

View details

Roido Manavaki

University of Cambridge

UNITED KINGDOM

View details

Nicole Mariani

King’s College London

UNITED KINGDOM

View details

Alejo Nevado-Holgado

University of Oxford

UNITED KINGDOM

View details

Dr Zuzanna Zajkowska

King’s College London

UNITED KINGDOM

View details

Karen Louise Randall

King’s College London

UNITED KINGDOM

View details

Naghmeh Nikkheslat

King’s College London

UNITED KINGDOM

View details

Marta Vicente-Rodríguez

Profesora Farmacología

Universidad CEU San Pablo

SPAIN

View details

Annamaria Cattaneo

University of Milan

ITALY

View details

Julia Schubert

King’s College London

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Zoe Hughes

Research Interests

Explore related searches

Contact this professor

Articles (10)

GM-1020: a novel, orally bioavailable NMDA receptor antagonist with rapid and robust antidepressant-like effects at well-tolerated doses in rodents

GM-1020: a novel, orally bioavailable NMDA receptor antagonist with rapid and robust antidepressant-like effects at well-tolerated doses in rodents.

First-in-Human Evaluation of 18F-PF-06445974, a PET Radioligand That Preferentially Labels Phosphodiesterase-4B

The novel persistent sodium current inhibitor PRAX-562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers

The novel persistent sodium current inhibitor PRAX-562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers.

Translational Pharmacology of PRAX-944, a Novel T-Type Calcium Channel Blocker in Development for the Treatment of Essential Tremor

Translational Pharmacology of PRAX-944, a Novel T-Type Calcium Channel Blocker in Development for the Treatment of Essential Tremor.

A Modest Increase in <sup>11</sup>C-PK11195-Positron Emission Tomography TSPO Binding in Depression Is Not Associated With Serum C-Reactive Protein or Body Mass Index

Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole Series.

Discovery of the First Orally Available, Selective K(Na)1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole Series

Collaborators (10)

Gerard Marek

Roido Manavaki

Nicole Mariani

Alejo Nevado-Holgado

Dr Zuzanna Zajkowska

Karen Louise Randall

Naghmeh Nikkheslat

Marta Vicente-Rodríguez

Annamaria Cattaneo

Julia Schubert

Make your next move.